CB Therapeutics raises Series A round with re.Mind Capital and accelerates its manufacturing and research of cannabinoids, tryptamines, and other therapeutics. Christian Angermayer joins as Advisor; the board of directors expands with additions of Dr. Srinivas Rao, CSO of Atai Life Sciences; Dr. Jeff Miller, CEO of Invivoscribe; and Jan Hardorp, Founding Partner at re.Mind Capital.


Previous articlePsychedelic Therapy for Borderline Personality Disorder?
Next articlePT243 – Dr. Fernando Espi Forcen and Dr. Franklin King of MGH’s Center for the Neuroscience of Psychedelics